| Gouill, Steven Le |
ECLECTIC, NCT06195709: EstroTEP and Circulating Biomarkers for ER-positive HER2-negative Metastatic Breast Cancer Patients |
|
|
| Recruiting | 3 | 300 | Europe | Endocrine therapy, Standardized endocrine therapy regimen, Endocrine therapy combined with the local treatment of FES-negative lesions, Chemotherapy, Standardized chemotherapy regimen | Institut Curie, Zionexa | Breast Carcinoma | 09/28 | 09/29 | | |
SYMPHONY-1, NCT04224493 / 2019-003333-42: A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma. |
|
|
| Recruiting | 3 | 612 | Europe, Canada, US, RoW | Tazemetostat, EPZ-6438, IPN60200, Placebo oral tablet, Lenalidomide, Rituximab | Epizyme, Inc. | Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma | 03/26 | 03/29 | | |
|
|
|
|
|
|
|
| Active, not recruiting | 2 | 86 | Europe | Obinutuzumab, GA, GA101, Dexamethasone, Aracytine, Cytarabine, Cisplatinum, Etoposide, Melphalan, Carmustine, BiCNU, BCNU | The Lymphoma Academic Research Organisation | Mantle Cell Lymphoma | 03/19 | 03/25 | | |
|
ALYCANTE, NCT04531046: Axi-Cel as a 2nd Line Therapy in Patients With Relapsed/Refractory Aggressive B Lymphoma Ineligible to Autologous Stem Cell Transplantation |
|
|
| Active, not recruiting | 2 | 62 | Europe | axicabtagene ciloleucel, axi-cel | The Lymphoma Academic Research Organisation | B-Cell Lymphoma Refractory, B-cell Lymphoma Recurrent | 04/22 | 06/26 | | |
| Active, not recruiting | 2 | 67 | Europe | Obinutuzumab, gazyva, RO7082859, glofitamab | The Lymphoma Academic Research Organisation | Diffuse Large B-Cell Lymphoma Refractory, Refractory Indolent Adult Non-Hodgkin Lymphoma, Refractory Transformed B-cell Non-Hodgkin Lymphoma, Refractory Primary Mediastinal Large B-Cell Cell Lymphoma, Refractory Mantle Cell Lymphoma | 01/23 | 03/26 | | |
| Active, not recruiting | 2 | 141 | Europe | Valemetostat tosylate, DS-3201b | The Lymphoma Academic Research Organisation, Daiichi Sankyo | Lymphoma, B-Cell | 10/24 | 10/24 | | |
| Recruiting | 2 | 214 | Europe | Chemotherapy monitoring by circulating tumor DNA analysis | Institut Curie | HER2-negative Metastatic Breast Cancer | 10/26 | 10/26 | | |
| Recruiting | 2 | 56 | Europe | Lacutamab, Gemcitabine, Oxaliplatine | The Lymphoma Academic Research Organisation, Innate Pharma | Peripheral T Cell Lymphoma, Relapse/Recurrence | 01/25 | 01/27 | | |
|
GLOASIS, NCT06558604: A Phase II Study Evaluating Glofitamab in Combination With Venetoclax Plus Zanubrutinib or Venetoclax Alone in Subjects With Untreated or Relapsed/Refractory High-risk Mantle-cell Lymphoma |
|
|
| Recruiting | 2 | 100 | Europe | Obinutuzumab, Glofitamab, Venetoclax Oral Product, Zanubrutinib Oral Capsule | The Lymphoma Academic Research Organisation, BeiGene, Hoffmann-La Roche | Lymphoma, Mantle-Cell | 05/28 | 03/32 | | |
OASIS-II, NCT04802590: Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell Lymphoma |
|
|
| Recruiting | 2 | 194 | Europe | Ibrutinib 560 mg, Venetoclax 10 MG Oral Tablet [Venclexta], Venetoclax 50 MG Oral Tablet [Venclexta], Venetoclax 100 MG Oral Tablet [Venclexta] | The Lymphoma Academic Research Organisation, Institute of Cancer Research, United Kingdom | Mantle Cell Lymphoma | 03/26 | 09/31 | | |
| Active, not recruiting | 1/2 | 48 | Europe | Ibrutinib + GA101 +GDC-0199, GA101 : Obinutuzumab, Ibrutinib, GDC-0199 | Nantes University Hospital, Janssen, LP, Roche Pharma AG | Mantle Cell Lymphoma | 04/19 | 10/25 | | |
| Recruiting | 1/2 | 118 | Europe, RoW | Lenalidomide, Revlimid, Ibrutinib, Imbruvica | Institut Curie, National Cancer Institute, France | Lymphoma, Large B-Cell, Diffuse, Central Nervous System Neoplasms, Primary | 02/25 | 02/35 | | |
neoBREASTIM, NCT06067061: "": Atezolizumab Plus RP1 Oncolytic Immunotherapy in the NeoAdjuvant Setting of Triple-Negative Breast Cancer |
|
|
| Recruiting | 1/2 | 51 | Europe | Atezolizumab + RP1, Tecentriq®, Vusolimogene Oderparepvec | Institut Curie, Replimune Inc., Roche Pharma AG | Triple Negative Breast Neoplasms | 04/26 | 04/31 | | |
REVCCI, NCT04804735: Use of Virtual Reality Mask or Music Therapy for Analgesia and Anxiolytic Purpose When Totally IVAD for Chemotherapy Under Local Anesthesia |
|
|
| Active, not recruiting | N/A | 127 | Europe | REV : local anesthesia and virtual reality, MUS : local anesthesia and music therapy | Institut Curie | Implanted Venous Access Device | 08/23 | 03/24 | | |
| Recruiting | N/A | 5000 | Europe | | The Lymphoma Academic Research Organisation, Gilead Sciences, Novartis, Bristol-Myers Squibb | Hematopathology Eligible or CAR-t Cell Treatment | 12/38 | 12/38 | | |
| RAT, Cédric |
SCOPE HPE, NCT06420128: Interprofessional Collaborative Practice in Primary Care: Potentially Avoidable Hospitalization |
|
|
| Not yet recruiting | N/A | 500000 | Europe | Primary care team | Nantes University Hospital | Hospitalization, Aged, Primary Health Care | 12/24 | 12/24 | | |
DEDICACES2, NCT05607849: Breast Cancer Screening Uptake: a Randomized Controlled Trial Assessing the Effect of a Decisional Aid |
|
|
| Not yet recruiting | N/A | 20000 | NA | The decidons ensemble (let's decide together) leaflet and the discutons-mammo.fr (let's talk about breast cancer screening) online tool. | Nantes University Hospital, National Cancer Institute, France, Nantes University hospital, Research Department | Breast Cancer | 06/25 | 09/25 | | |
| Recruiting | N/A | 350 | Europe | Active luminette, Placebo luminette | University Hospital, Strasbourg, France | Insomnia Chronic, Sleep Disorder, Circadian Rhythm Disorders | 02/25 | 02/25 | | |
